BMO Capital Maintains Outperform on AbbVie, Lowers Price Target to $180
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman maintains an Outperform rating on AbbVie (NYSE:ABBV) but lowers the price target from $195 to $180.

April 29, 2024 | 2:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BMO Capital maintains an Outperform rating on AbbVie but lowers the price target from $195 to $180.
The adjustment in price target by BMO Capital, while maintaining an Outperform rating, suggests a positive outlook on AbbVie's performance but with a slightly moderated growth expectation. This could lead to a neutral short-term impact on AbbVie's stock price as the market digests the revised target alongside the continued positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100